Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- -
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04343768
- Locations
- 🇮🇷
Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
Trial of Treatments for COVID-19 in Hospitalized Adults
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-11-29
- Target Recruit Count
- 1552
- Registration Number
- NCT04315948
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Martinique, Fort De France, France
🇫🇷Centre Hospitalier Andrée Rosemon, Cayenne, France
🇫🇷CHU APHP Ambroise-Paré, Boulogne-Billancourt, France
Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 40
- Registration Number
- NCT03614715
- Locations
- 🇫🇮
CRST Oy, Clinical Research Services Turku Itäinen Pitkäkatu 4 B, 3rd floor, Turku, Finland
A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Synairgen Research Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT03570359
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Celerion, Belfast, United Kingdom
🇬🇧Bradford Royal Infirmary, Bradford, United Kingdom
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT03177083
- Locations
- 🇵🇹
Hospital Fernando Fonseca, Amadora, Portugal
🇵🇹Hospital Evora, Evora, Portugal
🇵🇹Hospital de Braga, Braga, Portugal
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
- Conditions
- Interventions
- First Posted Date
- 2017-04-19
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT03119701
- Locations
- 🇱🇹
Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania
🇫🇮Central Finland Central Hospital, Jyväskylä, Finland
🇪🇪Tartu University Hospital, Tartu, Estonia
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT02937285
- Locations
- 🇫🇷
CHU Rennes, Rennes, France
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)
- Conditions
- Interventions
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 301
- Registration Number
- NCT02622724
- Locations
- 🇧🇪
Erasmus Hospital, Brussels, Belgium
🇫🇮Tampere University Hospital, Tampere, Finland
🇫🇷CHU De Poitiers, Poitiers, Poitou-Charentes, France
Phase I BP Interferon (IFN) Beta-001
- Conditions
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 12
- Registration Number
- NCT02515695
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.